Formulation, Evaluation, and Characterization of Ibuprofen Nanocrystals Tablets with Conventional Market Product

Chauhan, Nikita N; Patel, Jayvadan K

Abstract

Formulation, Evaluation, and Characterization of Ibuprofen Nanocrystals Tablets with Conventional Market Product

Author(s): Chauhan Nikita N, Patel Jayvadan K

Issue: Jan/Feb 2023 - Volume 27, Number 1

View All Articles in Issue

Page(s): 60-71

Download in electronic PDF format for $75

Abstract

The objective of this study was to prepare and evaluate ibuprofen nanocrystals using isopropyl alcohol and stabilizer sodium lauryl sulphate by way of the precipitation method. The nanocrystals were prepared by the bottom-up approach of the precipitation technique. This technique involves the use of an organic phase, which is completely miscible in the external aqueous phase. The ratio used for organic solvent-to-aqueous solvent was 1:50. The Fourier Transform Infrared Spectroscopy analyses confirmed that the drug and excipients were compatible, and the differential scanning calorimetry results indicated that the precipitation method led to no change in the crystalline structure of the drug. Scanning electron microscopy analysis of ibuprofen nanocrystals showed the promising size reduction of pure drug ibuprofen. Differential light scattering technique showed significant decrease in particle size and good stability of ibuprofen nanocrystals. Ibuprofen nanocrystals increased 20% to 25% of the saturation solubility of ibuprofen nanocrystals. Ibuprofen nanocrystals showed 90% drug release in the dissolution medium within 1 hour, while the pure drug and market product were dissolved only up to 58% and 63%, respectively. Ibuprofen nanocrystals increased the saturation solubility and in vitro dissolution of the drug as compared to conventional market product.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 2023 Pg. 60-71	Formulation, Evaluation, and Characterization of Ibuprofen Nanocrystals Tablets with Conventional Market Product Author(s): Chauhan Nikita N, Patel Jayvadan K
Mar/Apr 2004 Pg. 101-105	Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
May/Jun 2020 Pg. 227	Ibuprofen 400-mg and Cyclobenzaprine 2.5-mg Capsules Author(s): Allen Loyd V Jr
May/Jun 2011 Pg. 245	Ketoprofen 10%, Ibuprofen 10%, Cyclobenzaprine Hydrochloride 2%, and Piroxicam 2% in Pluronic Lecithin Organogel Gel Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 320	Sumatriptan, Lidocaine Hydrochloride, Dexamethasone, Pentoxifylline, and Ibuprofen Transdermal Cream (Migraine Cream) Author(s): Allen Loyd V Jr
May/Jun 2011 Pg. 244	Ibuprofen 5% Topical Cream Author(s): Allen Loyd V Jr
Jan/Feb 2011 Pg. 66	Ibuprofen 5% Gel Author(s): Allen Loyd V Jr
Jan/Feb 2013 Pg. 67	Ibuprofen 10-mg/mL Injection Author(s): Allen Loyd V Jr
Nov/Dec 1999 Pg. 496-500	Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations Author(s): Goodwin Donald A, Fuhram L Clifton
Jan/Feb 2023 Pg. 72-77	Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base Author(s): Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Sep/Oct 2023 Pg. 431-439	The Influence of Polymers, Surfactants, and Other Excipients on Naproxen Sodium Release from Matrices Prepared and the Effect of These Additives on the Swelling Rate of the Tablet Author(s): Alhmoud Hassan, Akkam Yazan, Omari Derar, Alghananim Alaa, Melhem Mohammad Bani
Nov/Dec 2023 Pg. 474-481	Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Author(s): Allen Loyd V Jr
Jul/Aug 2004 Pg. 292-293	Standard Operating Procedure: Determining and Documenting the Commercial Unavailability of a Manufactured Drug Product Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 418-425	Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3) Author(s): Bakhteyar Hamid, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
Mar/Apr 2021 Pg. 146-155	In Vitro Permeability, Irritability, and Release Evaluation of Commonly Used Topical Diclofenac Gel Preparations (1%, 5%, and 10%) Author(s): Kohan Hamed Gilzad, Baker David M, Sani Shabnam, Bielecki-Wilken Kathleen A, Ramirez Alfonso
Sep/Oct 2004 Pg. 388	Ibuprofen 2% Topical Gel Author(s): Allen Loyd V Jr
Jan/Feb 2000 Pg. 36-38	Marketing Your Prescription Compounding Practice: Part One Author(s): Letendre William R, Jackson Richard A
Jul/Aug 2023 Pg. 340-346	Formulation and In Vitro Evaluation of a Ramipril Entrapped in a Microsponge-based Drug-delivery System Author(s): Taghi Hassanien Sagban, Abdulbaqi Mustafa R, Samein Laith Hamza, Rahmani Maha H Philip
Jan/Feb 2003 Pg. 44-45	Determining the Availability of a Commercial Drug Author(s):
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr